Epileptic Disorders


Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs. An ILAE Commission Review Volume 21, numéro 4, August 2019

  • [Chen et al., 2011] Chen P., Lin J.J., Lu C.S. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364:1126-1133.
  • [Chen et al., 2016] Chen Z., Liew D., Kwan P. Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment. Neurology. 2016;86:1086-1094.
  • [Cheung et al., 2013] Cheung Y.K., Cheng S.H., Chan E.J. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54:1307-1314.
  • [Christensen et al., 1999] Christensen B., Arbour L., Tran P. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet. 1999;84:151-157.
  • [Chung et al., 2004] Chung W.H., Hung S.I., Hong H.S. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486.
  • [Dean et al., 2007] Dean J., Robertson Z., Reid V. Fetal anticonvulsant syndromes and polymorphisms in MTHFR, MTR, and MTRR. Am J Med Genet A. 2007;143A:2303-2311.
  • [Depondt et al., 2011] Depondt C., Godard P., Espel R.S., Da Cruz A.L., Lienard P., Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol. 2011;18:1159-1164.
  • [Dong et al., 2012] Dong D., Sung C., Finkelstein E.A. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology. 2012;79:1259-1267.
  • [Duncan et al., 2001] Duncan S., Mercho S., Lopes-Cendes I. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia. 2001;42:750-753.
  • [Hung et al., 2010] Hung S.I., Chung W.H., Liu Z.S. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11:349-356.
  • [Kim et al., 2011] Kim S.H., Lee K.W., Song W.J. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011;97:190-197.
  • [Kulkantrakorn et al., 2012] Kulkantrakorn K., Tassaneeyakul W., Tiamkao S. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract. 2012;12:202-208.
  • [Kuo, 1998] Kuo C.C. A common anticonvulsant binding site for phenytoin, carbamazepine and lamotrigine in neuronal Nachannels. Mol Pharmacol. 1998;54:712-721. +
  • [Lee et al., 2002] Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12:251-263.
  • [Lonjou et al., 2006] Lonjou C., Thomas L., Borot N. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 2006;6:265-268.
  • [Loscher et al., 2009] Loscher W., Klotz U., Zimprich F. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009;50:1-23.
  • [Man et al., 2007] Man C.B., Kwan P., Baum L. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48:1015-1018.
  • [McCormack et al., 2011] McCormack M., Alfirevic A., Bourgeois S. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364:1134-1143.
  • [McCormack Gui et al., 2018] McCormack Gui H., Ingason A. Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology. 2018;90:e332-e341.
  • [Mehta et al., 2009] Mehta T.Y., Prajapati L.M., Mittal B. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009;75:579-582.
  • [Omtzigt et al., 1992] Omtzigt J.G., Los F.J., Grobbee D.E. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology. 1992;42:119-125.
  • [Ozeki et al., 2011] Ozeki T., Mushiroda T., Yowang A. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20:1034-1141.
  • [Perucca and Gilliam, 2012] Perucca P., Gilliam F.G. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792-802.
  • [Plumpton et al., 2015] Plumpton C.O., Yip V.L., Alfirevic A., Marson A.G., Pirmohamed M., Hughes D.A. Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia. 2015;56:556-563.
  • [Schiavone et al., 2017] Schiavone S., Neri M., Pomara C., Riezzo I., Trabace L., Turillazzi E. Personalized medicine in the paediatric population: the balance between pharmacogenetic progress and bioethics. Curr Pharm Biotechnol. 2017;18:253-262.
  • [Shi et al., 2011] Shi Y.W., Min F.L., Liu X.R. Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. Basic Clin Pharmacol Toxicol. 2011;109:42-46.
  • [Shi et al., 2012] Shi Y.W., Min F.L., Qin B. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502. Basic Clin Pharmacol Toxicol. 2012;111:58-64.
  • [Stewart et al., 2010] Stewart J.D., Horvath R., Baruffini E. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology. 2010;52:1791-1796.
  • [Then et al., 2011] Then S.M., Rani Z.Z., Raymond A.A. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol. 2011;29:290-293.
  • [US Food and Drug Administration, 2011] U.S. Food and Drug Administration. Information on carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). 2015. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107834.html
  • [Wang et al., 2011] Wang Q., Zhou J.Q., Zhou L.M. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure. 2011;20:446-448.
  • [World Health Organization, 1972] World Health Organization. International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser 1972; 498: 1-25.
  • [Zhang et al., 2011] Zhang Y., Wang J., Zhao L.M. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol. 2011;67:885-887.